bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-70-2512

Order Name:
Factor II Gene Mutation

 
Useful For:
This test is intended to provide results for Factor II (G20210A) mutations as an aid in the diagnosis in individuals with suspected thrombophilia.
 
Methodology:
Multiplex real-time polymerase chain reaction (PCR)
 
AliasesName:
Prothrombin G20210A Mutation
Factor II 20210 mutation
Prothrombin 20210 mutation
 
 
 
Test Code:
090-70-2512

Order Name:
Factor II Gene Mutation

 
Collection Specimen Or Container:
Blood/ K3 EDTA (Lavender Top) 3 mL, 1 tube
 
Specimen Testing Type:
Whole blood, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: N/A
Lipemia: N/A
Icterus: N/A
Other :
  1. Heparin, anticoagulant blood
  2. Whole blood is stored at room temperature longer than 24 hr.
 
Specimen Stabillity:
Specimen Type Temperature Time
Whole blood, EDTA Room temperature, 22oC to 28oC 24 hours
Refrigerated, 2oC to 8oC 15 days
Frozen, -20oC to -80oC  3 months
 
 
 
Test Code:
090-70-2512

Order Name:
Factor II Gene Mutation

 
Method detail:
Multiplex real-time polymerase chain reaction (PCR)
 
Schedule:
Test daily
 
Turnaround Time:
Received specimen to reported within 1 day.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
090-70-2512

Order Name:
Factor II Gene Mutation

 
 
Clinical Information:
The association of Factor II (G20210A) mutations with an increased risk for venous thrombosis has been well documented. The Factor II or Prothrombin (G20210A) mutation refers to the G to A transition at nucleotide 20210 in the 3' untranslated region of the gene and is associated with increased plasma levels of prothrombin. Factor II (G20210A) mutations are present in 2% of the general population.
 
Reference Value:
No Mutation of the G20210A prothrombin gene
 
Interpretation:
  1. The results ot the test assay should be interpreted in conjunction with other laboratory and clinical data available to the clinician.
  2. Rare Factor II mutations and any additional SNPs in the probe binding region may interfere with the target detection and yield an INVALID result.
 
Clinical Reference:
Manufacturer’s packages insert, Xpert® Factor II & Factor V Assay, August 2017, Cepheid, CA 94089 Sunnyvale, USA.